MedTrace Logo

Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes

NCT03473262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-10-19

No results posted yet for this study

Summary

This study evaluates the efficacy and safety of the empagliflozin as add-on thearpy compared to insulin glargine-based antidiabetic agents (OADs) combination thearpy in patients with type 2 diabetes inadequately controlled on triple OADs in a real clinical practice.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • Chungbuk National University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-07-18
Completion
2018-07-18

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03473262 on ClinicalTrials.gov